Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

PureTech Health

Investor type Venture Capital
Founders Daphne Zohar John Zabriskie

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 23
Average round size
info
The average size of a deal this fund participated in
$27M
Portfolio companies 11
Rounds per year 1.10
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.52
Exits 4
Key employees 1

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
Summary

The company was established in North America in United States. The main office of represented Corporate Investor is situated in the Boston.

The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the PureTech Health, startups are often financed by InterWest Partners, Wellcome Trust, Polaris Partners. The meaningful sponsors for the fund in investment in the same round are InterWest Partners, Polaris Partners, Wellcome Trust. In the next rounds fund is usually obtained by New Enterprise Associates, InterWest Partners, Prospect Venture Partners.

This organization was formed by Daphne Zohar, John Zabriskie.

The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2008. This PureTech Health works on 14 percentage points less the average amount of lead investments comparing to the other organizations. Considering the real fund results, this Corporate Investor is 0 percentage points less often commits exit comparing to other organizations. The increased amount of exits for fund were in 2019. The usual things for fund are deals in the range of 10 - 50 millions dollars.

Among the most popular portfolio startups of the fund, we may highlight Vedanta Biosciences, Gelesis, Akili Interactive Labs. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Clinical Trials, Medical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of PureTech Health:
Typical Co-investors
PureTech Health is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after PureTech Health:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Adaptive Healthcare Fund California, Los Angeles, United States
Applegreen Partners -
Bank Hapoalim Israel, Tel Aviv, Tel Aviv District
Capitol Health Ltd Australia, Docklands, Victoria
Cedar Point Capital Minnesota, Saint Louis Park, United States
Fireca -
Forbes Family Trust New York, New York, United States
Great Stuff Ventures -
LATINIA Barcelona, Catalonia, Spain
Milestone Partners Pennsylvania, Radnor, United States
Nurmiranta Holdings -
Oxford Technology Management Oxford, Oxfordshire, United Kingdom
Ping An Capital China, Shanghai
ResMed California, San Diego, United States
Wentou Jianyuan Guanli Touzi China, Shaanxi, Xianyang
Winton Labs England, London, United Kingdom

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Vedanta Biosciences

Biotechnology
Business Development
Drug Discovery
Medical
$43M21 Jul 2021 Cambridge, Massachusetts, United States

Vor Biopharma

Biotechnology
Health Care
Pharmaceutical
$110M07 Jul 2020 Cambridge, Massachusetts, United States

Karuna Therapeutics

Biotechnology
Health Care
Pharmaceutical
$68M18 Mar 2019 Boston, Massachusetts, United States

Vedanta Biosciences

Biotechnology
Business Development
Drug Discovery
Medical
$45M24 Dec 2018 Cambridge, Massachusetts, United States

Karuna Therapeutics

Biotechnology
Health Care
Pharmaceutical
$42M02 Aug 2018 Boston, Massachusetts, United States

resTORbio

Biopharma
Biotechnology
Clinical Trials
Medical
$25M01 Jan 2017 Boston, Massachusetts, United States

Vedanta Biosciences

Biotechnology
Business Development
Drug Discovery
Medical
$50M06 Jun 2016 Cambridge, Massachusetts, United States

Akili Interactive Labs

Biotechnology
Health Care
Medical
Medical Device
Neuroscience
Therapeutics
$30M22 Jan 2016 Boston, Massachusetts, United States

Gelesis

Biotechnology
Diabetes
Health Care
Medical Device
$31M18 Dec 2015 Boston, Massachusetts, United States
News
Vedanta Biosciences Raises $68M in Series D Financing

– Vedanta Biosciences, Inc. from Cambridge, MA develops new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks.
– The company closed a $68m Series D financing.
– The round was led by affiliates of Magnetar Capital with participation from Verition Fund Management, Fosun Health Capital, co-founder PureTech Health (Nasdaq: PRTC, LSE: PRTC), Rock Springs Capital, Skyviews Life Science, JSR Corporation, SymBiosis LLC, Shumway Capital, Health for Life Capital (Seventure Partners), and other institutional investors.
– The company plans to use the funds to advance its pipeline of defined bacterial consortia, including progressing VE303 into a Phase 3 clinical trial in patients at high risk for recurrentCDI, initiating a Phase 2 clinical trial of VE202 in mild to moderate ulcerative colitis, and continuing to advance programs in additional indications.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent PureTech Health?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: